Navigation Links
Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting
Date:12/2/2009

age was 600 mg/day), and is more common in the elderly.

Severe congestive heart failure and left ventricular dysfunction have occasionally been reported. Most of the patients with reported cardiac events have had other comorbidities and risk factors, including advanced age and previous medical history of cardiac disease. Patients with cardiac disease or risk factors for cardiac failure should be monitored carefully, and any patient with signs or symptoms consistent with cardiac failure should be evaluated and treated.

Hepatotoxicity, occasionally severe, may occur. Assess liver function before initiation of treatment and monthly thereafter or as clinically indicated. Monitor liver function when combined with chemotherapy known to be associated with liver dysfunction. A 25% decrease in the recommended dose should be used for patients with severe hepatic impairment.

Patients with moderate renal impairment (CrCL = 20-39 mL/min) should receive a 50% decrease in the recommended starting dose, and future doses can be increased as tolerated. Doses greater than 600 mg/day are not recommended in patients with mild renal impairment (CrCL = 40-59 mL/min). For patients with moderate renal impairment, doses greater than 400 mg/day are not recommended. Gleevec should be used with caution in patients with severe renal impairment.

In the newly diagnosed CML trial, 2% of patients had (NCI Grades 3/4) hemorrhage.

There have also been reports, including fatalities, of cardiac tamponade, cerebral edema, acute respiratory failure, and gastrointestinal (GI) perforation.

Bullous dermatologic reactions (eg, erythema multiforme and Stevens-Johnson syndrome) have also been reported. In some cases, the reaction recurred upon rechallenge. Several postmarketing reports describe patients able to tolerate the reintroduction of Gleevec at a lower dose with or without concomitant corticosteroids or antihistamines following resol
'/>"/>

SOURCE Novartis
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25

Related medicine technology :

1. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
2. DEFLUX(R) Significantly Reduces Urinary Tract Infections in Children With Vesicoureteral Reflux
3. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
4. Vidaza Significantly Extends Overall Survival by 74% in Phase 3 Trial in Myelodysplastic Syndromes (MDS)
5. Nexavar Significantly Improved Overall Survival in Phase 3 Asia-Pacific Liver Cancer Trial
6. Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER(R) Sirolimus-eluting Coronary Stent Compared to Taxus Stent
7. Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
8. Study Shows Vasopressin Receptor Antagonist VAPRISOL(R) (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hyponatremia
9. DOV 21,947 Demonstrates Significant Body Weight and BMI Reductions in Drug- Compliant Subjects in Phase Ib Clinical Study
10. FASgen Announces Significant Milestone in Its Cancer Drug Development Program
11. New Data Reveal Topical Divigel(R) (estradiol gel) 0.1% Significantly Reduces Frequency and Severity of Hot Flashes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)...  HealthLoop® released an app version of its doctor-patient ... and allows people to share medical device and activity ... technologies to enhance the HealthLoop experience for iPhone users, ... doctors between visits. "This new flood ... is exciting," says HealthLoop founder Dr. Jordan Shlain ...
(Date:9/30/2014)... VIEW, Calif. , Sept. 30, 2014 /PRNewswire/ ... tissue diagnostics market, Frost & Sullivan recognizes Ventana ... Roche Group, with the 2014 North American Frost ... to strict quality practices along with a focus ... Ventana a global leader in tissue-based cancer diagnostic ...
(Date:9/30/2014)... 2014  Georgia-Pacific Professional is a leading provider ... a wide range of away from home applications. ... in healthcare, including hospitals, long-term care facilities, surgical ... its healthcare products and solutions to the dental ... of infection control in the dental office," said ...
Breaking Medicine Technology:HealthLoop Integrates with Apple's HealthKit Enabling Patients to Share Health Data with Their Doctors Right from their iPhone 2Frost & Sullivan applauds the diversity of Ventana products and services for the cancer diagnostics market 2Frost & Sullivan applauds the diversity of Ventana products and services for the cancer diagnostics market 3Frost & Sullivan applauds the diversity of Ventana products and services for the cancer diagnostics market 4Georgia-Pacific Professional Brings Its Success in Medical Solutions to the Dental Community 2Georgia-Pacific Professional Brings Its Success in Medical Solutions to the Dental Community 3
... Mass., Nov. 11, 2010 Interleukin Genetics, Inc. (OTCQB: ILIU) ... ended September 30, 2010. Revenue for the three ... $0.3 million for the same period in the prior year. ... as we experience positive growth. Research and development ...
... NEW YORK, Nov. 11, 2010 /PRNewswire-Asia-FirstCall/ -- American ... ("the Company" or "AOBO"), a pharmaceutical company dedicated ... commercialization of a broad range of prescription and ... of AOBO Wujia Rongxue Oral Liquid, ("AWRO Liquid"), ...
Cached Medicine Technology:Interleukin Genetics Reports Third Quarter 2010 Financial Results 2Interleukin Genetics Reports Third Quarter 2010 Financial Results 3Interleukin Genetics Reports Third Quarter 2010 Financial Results 4Interleukin Genetics Reports Third Quarter 2010 Financial Results 5American Oriental Bioengineering Introduces Wujia Rongxue Oral Liquid 2
(Date:9/30/2014)... (PRWEB) September 30, 2014 The ... to improve breast cancer risk prediction and to ... a study published in Breast Cancer Research (BCR ... density and breast cancer risk: a case-control study ... strong connection between breast density and breast cancer ...
(Date:9/30/2014)... partners successfully established a visual mapping of the ... suppressor cells (MDSC). The damage and immune suppression ... this is a major stepping stone in creating ... factors from precursors present in hematopoietic organs such ... population of cells suppresses the activity of various ...
(Date:9/30/2014)... University of Eastern Finland shows that dietary polyunsaturated fatty ... The sources of polyunsaturated fatty acids include fish, vegetable ... Arteriosclerosis, Thrombosis & Vascular Biology , an esteemed journal ... not found an association between the consumption of saturated ... that the mere reduction of saturated fats from the ...
(Date:9/30/2014)... This two-day, advanced PT continuing education course ... may arise following a concussion or mild traumatic brain ... from sports related injuries, car accidents, falls, to the ... of returning soldiers from war zone regions. While at ... can result in similar injuries, the course will emphasize ...
(Date:9/30/2014)... By Dennis Thompson ... -- Every day, people receive medical implants -- artificial ... may not have been rigorously tested before or after their ... studies contend. The studies -- conducted by prominent nonprofit ... Medicine -- lay the blame for inadequate medical device ...
Breaking Medicine News(10 mins):Health News:Mammographic Density Offers Potential to Improve Prediction of Breast Cancer Risk and Development of Personalized Screening 2Health News:Mammographic Density Offers Potential to Improve Prediction of Breast Cancer Risk and Development of Personalized Screening 3Health News:Mammographic Density Offers Potential to Improve Prediction of Breast Cancer Risk and Development of Personalized Screening 4Health News:Dietary polyunsaturated fatty acids linked to smaller risk of coronary heart disease 2Health News:North American Seminars Presents Traumatic Brain Injury and Concussions in Conduction with St. Anthony's Medical Center in St. Louis, MO on November 8-9, 2014 2Health News:North American Seminars Presents Traumatic Brain Injury and Concussions in Conduction with St. Anthony's Medical Center in St. Louis, MO on November 8-9, 2014 3Health News:Medical Implant Devices Skate Through Review Process, Studies Claim 2Health News:Medical Implant Devices Skate Through Review Process, Studies Claim 3Health News:Medical Implant Devices Skate Through Review Process, Studies Claim 4
... these patients, researcher says , , FRIDAY, Oct. 10 (HealthDay ... 75 percent higher risk for developing colorectal cancer sometime ... syndrome is a conglomeration of three or four diseases, ... illnesses, including a number of cancers," said study co-author ...
... excellence in the implementation of electronic health records (EHRs), the ... of the 2008 Davies Awards in the Organizational, Ambulatory and ... ... Chicago, IL (PRWEB) October 10, 2008 -- Honoring excellence in ...
... Mich.---The University of Michigan received $5 million from the ... resource of high-quality experimental data sets of drug-making compounds ... new level. , The resource will house the ... the effectiveness of potential new drugs, said Heather Carlson, ...
... 10 The Johns Hopkins University School,of Medicine ... Breast Cancer Strategies: From Biomarkers to Treatment,Selection," to ... advances in,breast cancer treatment., In recent years, ... to chemotherapeutic and biologic treatment combinations that are,increasingly ...
... Mobile Massage Team, (http://www.mobilemassageteam.com ), a leading ... wellness programs, promotional events, and special,affairs, announced ... area throughout,eastern Pennsylvania and the greater Philadelphia ... about the increasing interest in our on-site,seated, ...
... nationally recognized faculty will,present the very latest treatment ... course "Optimizing Adjuvant Breast Cancer,Strategies: From Biomarkers to ... It is challenging for practicing oncologists and other ... on the latest patient care,advances. This accredited course ...
Cached Medicine News:Health News:Metabolic Syndrome Raises Colon Cancer Risk 75% 2Health News:Metabolic Syndrome Raises Colon Cancer Risk 75% 3Health News:2008 HIMSS Davies Awards: Nation's Outstanding Healthcare Organizations Recognized 2Health News:2008 HIMSS Davies Awards: Nation's Outstanding Healthcare Organizations Recognized 3Health News:2008 HIMSS Davies Awards: Nation's Outstanding Healthcare Organizations Recognized 4Health News:2008 HIMSS Davies Awards: Nation's Outstanding Healthcare Organizations Recognized 5Health News:U-M to house leading drug database 2Health News:Latest Research on Breast Cancer Presented in a Virtual E-Conference CME Course 2Health News:Mobile Massage Team Announces Expansion of On-Site Seated Massage Services Throughout Eastern Pennsylvania and the Greater Philadelphia Region 2Health News:Nationally Recognized Faculty Presents Latest Advances in Care of Patients with Breast Cancer 2
... For use as a ... detecting IgG antibody to Toxoplasma ... to rubella virus (rubella IgG), ... IgG) and IgG antibody to ...
... The VITROS HBsAg assay is ... by the U.S. Food and ... in a random,access format on ... Intellicheck. Now you can run ...
... The Total PSA method for ... immunoassay module is an in vitro ... total prostate specific antigen (TPSA) in ... used as an aid in the ...
... based on sequential binding of HCG from ... for the *-chain of HCG) immobilized on ... the *-chain of HCG) conjugated to the ... chromogenic substrate is added and colors developed. ...
Medicine Products: